AUG 25, 2020 8:20 AM PDT

Targeting Checkpoint Molecule Could Mean Checkmate for Cancer

WRITTEN BY: Tara Fernandes


In a new study published in Cell, researchers have identified a metabolic enzyme that could have powerful tumor-killing effects when targeted by immunotherapies. Interleukin-4-Induced-1, or IL4I1, is secreted in large quantities by tumors, naturally promoting the spread of cancers while simultaneously suppressing the immune system.

Immunotherapies are drug modality that works by either activating or quietening the immune system, helping the body to fight autoimmune conditions, infectious diseases, and cancer. For oncology applications, a variety of immunotherapies are currently available including T cell transfer therapies, monoclonal antibodies, cancer vaccines, and immune checkpoint inhibitors. While in theory, these approaches hold promise, clinical results have often fallen flat, leading researchers to identify fresh ways of boosting their efficacy on a molecular level.

IL4I1 was of particular interest to oncology researchers as a potential target because of its ability to promote cancer cell motility, dampen the adaptive immune response to cancer, and also its correlation with reduced survival in glioma (a malignant brain cancer) patients. The study’s authors saw similar observations in mouse models of glioma, as noted by study author Martina Seiffert from the German Cancer Research Center (DKFZ).

“In animals that do not produce IL4I1 in the tumor environment due to genetic alterations, the immune system is significantly more successful in preventing the cancer from progressing,” said Seiffert.

Their results put IL4I1 within the crosshairs as a prime target for future immunotherapies. As Christiane Opitz, a research group leader at DKFZ concludes, “IL4I1 has great potential as a target for drugs. So far, drugs that inhibit enzymes of the tryptophan metabolism have failed in clinical trials because the tumors did not respond to them. However, the role of IL4I1 has so far been disregarded, and this enzyme has not yet been tested as a target molecule.”

 

 

Sources: Cell, Genetic Engineering & Biotechnology News.


 

About the Author
Doctorate (PhD)
Interested in health technology and innovation.
You May Also Like
NOV 03, 2022
Clinical & Molecular DX
Co-Infections of COVID-19 and the Flu were Common Last Winter, Researchers Find
Co-Infections of COVID-19 and the Flu were Common Last Winter, Researchers Find
Infections of SARS-CoV-2, or COVID-19, do not always occur on their own. A COVID-19 infection can occur at the same time ...
NOV 17, 2022
Cancer
Anti-Aging Supplement Linked to Aggressive Breast Cancer
Anti-Aging Supplement Linked to Aggressive Breast Cancer
Vitamin B3, also known as niacin, is a generic name for a group of biochemical compounds, including nicotinamide ribosid ...
NOV 28, 2022
Immunology
New Insights Into How Fats Can Affect Immunity
New Insights Into How Fats Can Affect Immunity
Immunity is closely linked to metabolism, and in recent years, scientists have found that fat molecules, or lipids, can ...
JAN 13, 2023
Immunology
B Cell Surface Features Revealed by Advanced Microscopy
B Cell Surface Features Revealed by Advanced Microscopy
With an advanced technique called lattice light sheet microscopy, scientists have revealed structures on the surface of ...
JAN 16, 2023
Coronavirus
'Kraken' - Will This COVID Subvariant Outcompete Them All?
'Kraken' - Will This COVID Subvariant Outcompete Them All?
SARS-CoV-2, the virus that causes COVID-19 continues to cause huge numbers of infections around the world because of the ...
JAN 24, 2023
Immunology
Unprecedented Analysis of HIV Reservoir Cells Reveals Unique Properties
Unprecedented Analysis of HIV Reservoir Cells Reveals Unique Properties
HIV-1 is tenacious. It forms reservoirs that establish a life-long presence in the body - cells that are HIV-infected bu ...
Loading Comments...